|
Axatilimab Clinical Trials
4 actively recruiting trials across 4 locations
Also known as: Ab969.g2, Anti-M-CSFR Monoclonal Antibody SNDX-6352, C24H23FN4O3, SNDX 6352, SNDX-6352 +3 more
Pipeline
Phase 1: 1Phase 2: 1Phase 1/2: 2
Top Sponsors
- University of Utah1
- Uma Borate1
- OHSU Knight Cancer Institute1
- Dana-Farber Cancer Institute1
Indications
- Cancer4
- Refractory Myeloproliferative Neoplasm1
- Recurrent Myeloproliferative Neoplasm1
- Atypical Chronic Myeloid Leukemia1
- Chronic Myelomonocytic Leukemia1
Boston, Massachusetts1 trial
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Beth Israel Deaconess Medical Center
Phase 1
Detroit, Michigan1 trial
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Karmanos Cancer Institute
Phase 2
Columbus, Ohio1 trial
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2
Portland, Oregon1 trial
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.